C2i Genomics

company

About

C2i Genomics provides cloud-based cancer diagnostic services to pharmaceutical and diagnostic organizations.

  • 11 - 50

Details

Last Funding Type
Series B
Last Funding Money Raised
$100M
Industries
Genetics,Health Care,Health Diagnostics,Therapeutics
Founded date
Jan 1, 2019
Number Of Employee
11 - 50
Operating Status
Active

C2i Genomics provides cloud-based cancer diagnostic services to pharmaceutical and diagnostic organizations.

The cancer intelligence company is developing a platform that can perform whole-genome sequencing using only 2 milliliters of blood. Its ultra-sensitive liquid biopsy assay allows physicians to monitor patient treatment response and detect treatment failure or disease recurrence months and potentially years earlier than current monitoring methods. C2i’s cancer diagnostics service uses artificial intelligence pattern recognition and the whole-genome analysis to spot trace amounts of cancer much quicker, in about a week, to inform better treatment decisions and ultimately save lives. The company aims to help patients avoid unnecessary overtreatment with toxic chemotherapy or radiation, as well as to prevent them from going without treatment while cancer quietly grows and metastasizes.

In 2019, Boris Oklander, Asaf Zviran, and Ezra Sofer established the company in New York, New York.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$100M
C2i Genomics has raised a total of $100M in funding over 2 rounds. Their latest funding was raised on Apr 15, 2021 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Apr 15, 2021 Series B $100M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
C2i Genomics is funded by 1 investors. Silver Lake are the most recent investors.
Investor Name Lead Investor Funding Round
Silver Lake Series B